Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial

E Camenzind, W (William) Wijns, L Mauri, V Kurowski, Kaushal Parikh, RL Gao, C Bode, JP Greenwood, Eric Boersma, Pascal Vranckx, E McFadden, PWJC (Patrick) Serruys, WW O'Neil, B Jorissen, F van Leeuwen, PG Steg

Research output: Contribution to journalArticleAcademicpeer-review

139 Citations (Scopus)


Background We sought to compare the long-term safety of two devices with different antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and the Cypher sirolimus-eluting stent (C-SES; Cordis, Johnson & Johnson) in a broad group of patients and lesions. Methods Between May 21, 2007 and Dec 22, 2008, we recruited 8791 patients from 36 recruiting countries to participate in this open-label, multicentre, randomised, superiority trial. Eligible patients were those aged 18 years or older undergoing elective, unplanned, or emergency procedures in native coronary arteries. Patients were randomly assigned to either receive E-ZES and C-SES (ratio 1: 1). Randomisation was stratified per centre with varying block sizes of four, six, or eight patients, and Findings PROTECT randomised 8791 patients, of whom 8709 provided consent to participate and were eligible: 4357 were allocated to the E-ZES group and 4352 patients to the C-SES group. At 3 years, rates of definite or probable stent thrombosis did not differ between groups (1.4% for E-ZES [predicted: 1.5%] vs 1.8% [predicted: 2.5%] for C-SES; hazard ratio [HR] 0.81, 95% CI 0.58-1.14, p=0.22). Dual antiplatelet therapy was used in 8402 (96%) patients at discharge, 7456 (88%) at 1 year, 3041 (37%) Interpretation No evidence of superiority of E-ZES compared with C-SES in definite or probable stent thrombosis rates was noted at 3 years. Time analysis suggests a difference in definite or probable stent thrombosis between groups is emerging over time, and a longer follow-up is therefore needed given the clinical relevance of stent thrombosis.
Original languageUndefined/Unknown
Pages (from-to)1396-1405
Number of pages10
JournalLancet (UK)
Issue number9851
Publication statusPublished - 2012

Research programs

  • EMC COEUR-09

Cite this